Single-cell profiling of tumour evolution in multiple myeloma—opportunities for precision medicine
Multiple myeloma (MM) is a haematological malignancy of plasma cells characterized by
substantial intraclonal genetic heterogeneity. Although therapeutic advances made in the …
substantial intraclonal genetic heterogeneity. Although therapeutic advances made in the …
A comparison of the International Consensus and 5th World Health Organization classifications of mature B-cell lymphomas
Several editions of the World Health Organization (WHO) classifications of lympho-
hemopoietic neoplasms in 2001, 2008 and 2017 served as the international standard for …
hemopoietic neoplasms in 2001, 2008 and 2017 served as the international standard for …
The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee
Since the publication of the Revised European-American Classification of Lymphoid
Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have …
Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have …
Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma
BCMA targeting chimeric antigen receptor (CAR) T cell therapy has shown deep and
durable responses in multiple myeloma. However, relapse following therapy is frequently …
durable responses in multiple myeloma. However, relapse following therapy is frequently …
Genomic profiling for clinical decision making in lymphoid neoplasms
L De Leval, AA Alizadeh, PL Bergsagel… - Blood, The Journal …, 2022 - ashpublications.org
With the introduction of large-scale molecular profiling methods and high-throughput
sequencing technologies, the genomic features of most lymphoid neoplasms have been …
sequencing technologies, the genomic features of most lymphoid neoplasms have been …
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis
Patients with newly diagnosed multiple myeloma (NDMM) with high-risk disease are in need
of new treatment strategies to improve the outcomes. Multiple clinical, cytogenetic, or gene …
of new treatment strategies to improve the outcomes. Multiple clinical, cytogenetic, or gene …
Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation
J Derrien, S Gastineau, A Frigout, N Giordano… - Nature Cancer, 2023 - nature.com
Bispecific antibodies targeting GPRC5D demonstrated promising efficacy in multiple
myeloma, but acquired resistance usually occurs within a few months. Using a single …
myeloma, but acquired resistance usually occurs within a few months. Using a single …
Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens
Despite improving outcomes, 40% of patients with newly diagnosed multiple myeloma
treated with regimens containing daratumumab, a CD38-targeted monoclonal antibody …
treated with regimens containing daratumumab, a CD38-targeted monoclonal antibody …
Genomic landscape and chronological reconstruction of driver events in multiple myeloma
The multiple myeloma (MM) genome is heterogeneous and evolves through preclinical and
post-diagnosis phases. Here we report a catalog and hierarchy of driver lesions using …
post-diagnosis phases. Here we report a catalog and hierarchy of driver lesions using …
[HTML][HTML] Multiple myeloma: the (r) evolution of current therapy and a glance into the future
KC Anderson - Haematologica, 2020 - ncbi.nlm.nih.gov
Over the past 20 years, the regulatory approval of several novel agents to treat multiple
myeloma (MM) has prolonged median patient survival from 3 to 8-10 years. Increased …
myeloma (MM) has prolonged median patient survival from 3 to 8-10 years. Increased …